CriticalAntidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative×Antidepressant (other antidepressants, N06AX)
Updated · Methodology
Mechanism
Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) A and B and stops the enzyme from breaking down serotonin, norepinephrine and dopamine (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Vortioxetine can cause serotonin syndrome on its own, and the risk rises when it is combined with drugs that affect serotonin metabolism, MAO inhibitors included (vortioxetine SmPC, European Medicines Agency, EMA). MAO activity returns only 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine label, US Food and Drug Administration, FDA). The elimination half-life of vortioxetine is 66 hours (vortioxetine SmPC, EMA).
Symptoms
Serotonin syndrome with tranylcypromine and vortioxetine can be severe and life-threatening (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). It shows as changes in consciousness (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high body temperature), neuromuscular problems (overactive reflexes, poor coordination) and nausea, vomiting or diarrhoea. With monoamine oxidase inhibitors, vortioxetine also carries a higher risk of neuroleptic malignant syndrome (vortioxetine SmPC, European Medicines Agency, EMA). The US tranylcypromine label adds tremor, muscle rigidity, myoclonus and seizures. It reports fatal cases, including in people treated with tranylcypromine. With antidepressants that inhibit serotonin reuptake, the picture sometimes resembled neuroleptic malignant syndrome (tranylcypromine label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, which names vortioxetine; vortioxetine SmPC, European Medicines Agency, EMA, for irreversible non-selective monoamine oxidase inhibitors, MAOIs, the group tranylcypromine belongs to; tranylcypromine and vortioxetine labels, US Food and Drug Administration, FDA). Start vortioxetine at least 14 days after stopping tranylcypromine (vortioxetine SmPC, EMA, and FDA label; tranylcypromine SmPC, AEMPS). Start tranylcypromine at least 14 days after stopping vortioxetine under the EU vortioxetine SmPC (EMA), or at least 21 days under the US label (vortioxetine FDA label). For a switch from another antidepressant, the Spanish tranylcypromine SmPC recommends a drug-free interval of about 5 half-lives of the previous drug and its active metabolites (tranylcypromine SmPC, AEMPS). If serotonin syndrome develops, stop vortioxetine at once and start symptomatic treatment (vortioxetine SmPC, EMA). Stop tranylcypromine and any other serotonergic drug immediately as well (tranylcypromine FDA label). Treat severe serotonin syndrome caused by an interaction with serotonergic drugs as tranylcypromine poisoning, in intensive care. Monitor pulse, blood pressure, breathing and temperature closely and keep mechanical ventilation available (tranylcypromine SmPC, AEMPS). The same SmPC recommends benzodiazepines for severe agitation and/or marked muscle rigidity. Oral cyproheptadine may be tried to block serotonin receptors. At a body temperature of 40 °C or higher, start active cooling at once (tranylcypromine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.4 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, información del producto actualizada 19/01/2026, secciones 4.3, 4.4, 4.5 y 5.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.3 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, consultado 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.5 y 5.2
- FDA: TRINTELLIX (vortioxetine) tablets prescribing information (Takeda) (2025)– FDA, DailyMed setid 1a5b68e2-14d0-419d-9ec6-1ca97145e838 (Takeda Pharmaceuticals America), revisión 02/2025 (versión 18, vigente desde 05.03.2025), secciones 2.4, 4, 5.2 y 7.1